Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention

PAN Yuhui; SANG Wentao; BIAN Yuan; XU Feng

doi:10.12290/xhyxzz.2022-0627

Volume 14 Issue 3

May 2023

Turn off MathJax

Article Contents

Abstract

References

Medical Journal of Peking Union Medical College Hospital > 2023 > 14(3): 465-471. > DOI: 10.12290/xhyxzz.2022-0627

PAN Yuhui, SANG Wentao, BIAN Yuan, XU Feng. Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 465-471. DOI: 10.12290/xhyxzz.2022-0627

Citation:

PDF (1242 KB)

Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention

PAN Yuhui^{1, 2},
SANG Wentao^{1, 2},
BIAN Yuan^{1, 2, ,},
XU Feng^{1, 2, ,}

1.
Department of Emergency Medicine, Chest Pain Center, Qilu Hospital of Shandong University, Jinan 250012, China
2.
Shandong Provincial Clinical Research Center for Emergency & Critical Care Medicine, Jinan 250012, China

Funds:

National Key Research and Development Program of China 2020YFC1512700

Key Research and Development Program of Shandong Province 2021ZLGX02

Taishan Pandeng Scholar Program of Shandong Province tspd20181220

More Information

Corresponding author:
BIAN Yuan, E-mail: bianyuan@sdu.edu.cn

XU Feng, E-mail: xufengsdu@126.com
Received Date: October 30, 2022
Accepted Date: February 06, 2023
Available Online: February 19, 2023
Issue Publish Date: May 29, 2023

Graphical Abstract

Abstract

Abstract

Hypertrophic cardiomyopathy(HCM) is one of the most common hereditary cardiomyopathy, the most serious outcome of which is sudden cardiac death(SCD). Early recognition and prevention may delay or avoid the onset of cardiac arrest. Therefore, it is important to identify the high-risk factors of SCD in patients with HCM and prevent cardiac arrest. At present, the recognized high risk factors mainly include family history of sudden death, non-sustained ventricular tachycardia, severe left ventricular hypertrophy, unexplained syncope, end-stage HCM with left ventricular ejection fraction < 50%, left ventricular systolic dysfunction of any size, and extensive late gadolinium enhancement. The main preventive measures involvemedical treatment, surgical septal myectomy, alcohol septal ablation, and implantable cardiac defibrillator. This article mainly focuses on the identification of high-risk factors and prevention strategies of SCD caused by HCM, and reviews the latest progress of diagnosis, treatment and prevention of HCM, to provide guidance for prevention of SCD caused by HCM.
- hypertrophic cardiomyopathy,
- sudden cardiac death,
- high-risk factors,
- prevention

FullText(HTML)

References (43)

References

[1]	国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 中华医学会心血管分会心力衰竭学组, 等. 中国肥厚型心肌病指南2022[J]. 中华心力衰竭和心肌病杂志, 2022, 06: 80-105. DOI: 10.3760/cma.j.cn1101460-20220805-00070
[2]	Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy[J]. Heart, 2006, 92: 785-791. http://med.wanfangdata.com.cn/DocDeliveryPumch/Index/PeriodicalPaper_PM16216855
[3]	Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods[J]. Circulation, 1995, 92: 700-704. DOI: 10.1161/01.CIR.92.4.700
[4]	Crocker TF, Brown L, Lam N, et al. Information provision for stroke survivors and their carers[J]. Cochrane Database Syst Rev, 2021, 11: CD001919.
[5]	Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35: 2733-2779. DOI: 10.1093/eurheartj/ehu284
[6]	Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2020, 142: e533-e557. http://pubmed.ncbi.nlm.nih.gov/33229116/
[7]	Wu G, Liu J, Wang S, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy[J]. Heart, 2021, 107: 1576-1583. DOI: 10.1136/heartjnl-2020-317701
[8]	Bayonas-Ruiz A, Muñoz-Franco FM, Ferrer V, et al. Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis[J]. J Clin Med, 2021, 10: 2312. DOI: 10.3390/jcm10112312
[9]	Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J, 2022, 43: 3997-4126. DOI: 10.1093/eurheartj/ehac262
[10]	Geske JB, Ommen SR, Gersh BJ. Hypertrophic Cardiomyopathy: Clinical Update[J]. JACC Heart Fail, 2018, 6: 364-375. DOI: 10.1016/j.jchf.2018.02.010
[11]	Maron MS. Family History of Sudden Death Should Be a Primary Indication for Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy[J]. Can J Cardiol, 2015, 31: 1402-1406. DOI: 10.1016/j.cjca.2015.05.004
[12]	Liu Q, Li D, Berger AE, et al. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis[J]. Sci Rep, 2017, 7: 11957. DOI: 10.1038/s41598-017-12289-4
[13]	Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy[J]. Circulation, 2009, 119: 1703-1710. DOI: 10.1161/CIRCULATIONAHA.108.798314
[14]	Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events[J]. Pediatr cardiol, 2011, 32: 1096-1105. DOI: 10.1007/s00246-011-9967-y
[15]	Olivotto I, Gistri R, Petrone P, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2003, 41: 315-321. http://www.sciencedirect.com/science/article/pii/S0735109703008271
[16]	O'Mahony C, Jichi F, Monserrat L, et al. Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy[J]. Circ Arrhythm Electrophysiol, 2016, 9: e003818. DOI: 10.1161/CIRCEP.115.003818
[17]	Norrish G, Ding T, Field E, et al. Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy[J]. Circulation Arrhythm Electrophysiol, 2022, 15: e010075.
[18]	Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodel-ing in the end-stage phase of hypertrophic cardiomyopathy[J]. Circulation, 2006, 114: 216-225. DOI: 10.1161/CIRCULATIONAHA.105.583500
[19]	Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction[J]. J Am Coll Cardiol, 2020, 75: 3033-3043. http://www.sciencedirect.com/science/article/pii/S0735109720350920
[20]	Rowin EJ, Maron BJ, Chokshi A, et al. Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age[J]. Pacing Clin Electrophysiol, 2018, 41: 1031-1033. DOI: 10.1111/pace.13413
[21]	Adamczak DM, Oko-Sarnowska Z. Sudden Cardiac Death in Hypertrophic Cardiomyopathy[J]. Cardiol Rev, 2018, 26: 145-151. DOI: 10.1097/CRD.0000000000000184
[22]	Rowin EJ, Maron BJ, Haas TS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management[J]. J Am Coll Cardiol, 2017, 69: 761-773.
[23]	Kamp NJ, Chery G, Kosinski AS, et al. Risk stratification using late gadolinium enhancement on cardiac magnetic resonance imaging in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis[J]. Prog Cardiovasc Dis, 2021, 66: 10-16. DOI: 10.1016/j.pcad.2020.11.001
[24]	Weng Z, Yao J, Chan RH, et al. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis[J]. JACC Cardiovasc Imaging, 2016, 9: 1392-1402. DOI: 10.1016/j.jcmg.2016.02.031
[25]	Amano Y, Yanagisawa F, Kitamura M, et al. Relationship of Nonseptal Late Gadolinium Enhancement to Ventricular Tachyarrhythmia in Hypertrophic Cardiomyopathy[J]. J Comput Assist Tomogr, 41: 768-771. DOI: 10.1097/RCT.0000000000000599
[26]	Li X, Lai L, Luo R, et al. The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study[J]. J Cardiovasc Transl Res, 2021, 14: 1001-1016. DOI: 10.1007/s12265-021-10107-x
[27]	Aquaro GD, Grigoratos C, Bracco A, et al. Late Gadolinium Enhancement-Dispersion Mapping: A New Magnetic Resonance Imaging Technique to Assess Prognosis in Patients With Hypertrophic Cardiomyopathy and Low-Intermediate 5-Year Risk of Sudden Death[J]. Circ Cardiovasc Imaging, 2020, 13: e010489-e010489. DOI: 10.1161/CIRCIMAGING.120.010489
[28]	Shen H, Dong SY, Ren MS, et al. Ventricular arrhythmia and sudden cardiac death in hypertrophic cardiomyopathy: From bench to bedside[J]. Front Cardiovasc Med, 2022, 9: 949294. DOI: 10.3389/fcvm.2022.949294
[29]	Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors[J]. Heart rhythm, 2012, 9: 57-63. DOI: 10.1016/j.hrthm.2011.08.009
[30]	Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy[J]. Circulation, 1997, 96: 2987-2991. DOI: 10.1161/01.CIR.96.9.2987
[31]	Maron BJ, Rowin EJ, Casey SA, et al. Risk stratification and outcome of patients with hypertrophic cardiomyopathy≥60 years of age[J]. Circulation, 2013, 127: 585-593. DOI: 10.1161/CIRCULATIONAHA.112.136085
[32]	Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy[J]. Eur Heart J, 2006, 27: 1933-1941 DOI: 10.1093/eurheartj/ehl041
[33]	Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2016, 18: 891-975. DOI: 10.1002/ejhf.592
[34]	Coats CJ, Gallagher MJ, Foley M, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy[J]. Eur Heart J, 2013, 34: 2529-2537. DOI: 10.1093/eurheartj/eht070
[35]	Sun XG, Hansen JE, Beshai JF, et al. Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure[J]. J Am Coll Cardiol, 2010, 55: 1814-1823. DOI: 10.1016/j.jacc.2009.10.075
[36]	Coats CJ, Rantell K, Bartnik A, et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy[J]. Circ Heart Fail, 2015, 8: 1022-1031. DOI: 10.1161/CIRCHEARTFAILURE.114.002248
[37]	Finocchiaro G, Haddad F, Knowles JW, et al. Cardiopul-monary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment[J]. JACC Heart fail, 2015, 3: 408-418. DOI: 10.1016/j.jchf.2014.11.011
[38]	Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396: 759-769. DOI: 10.1016/S0140-6736(20)31792-X
[39]	Maron BJ, Rowin EJ, Casey SA, et al. How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice[J]. JAMA cardiol, 2016, 1: 98-105. DOI: 10.1001/jamacardio.2015.0354
[40]	Desai MY, Smedira NG, Dhillon A, et al. Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: Potential for refinement of current criteria[J]. J Thorac Cardiovasc Surg, 2018, 156: 750-759. DOI: 10.1016/j.jtcvs.2018.03.150
[41]	Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience[J]. Clin Res Cardiol, 2008, 97: 234-243. DOI: 10.1007/s00392-007-0616-7
[42]	Bytyçi I, Nistri S, Mörner S, et al. Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis[J]. J Clin Med, 2020, 9: 3062. DOI: 10.3390/jcm9103062
[43]	Maron MS, Rowin EJ, Wessler BS, et al. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy[J]. JAMA cardiol, 2019, 4: 644-657. DOI: 10.1001/jamacardio.2019.1391

[1]	LOU Ying, CAI Jun. Moving Forward the Defense Line and Wasting No Time: The Era of Active Prevention and Control of Hypertension in China Has Come[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1238-1241. DOI: 10.12290/xhyxzz.2024-0774
[2]	LI Tao, YANG Tongnan, LIU Bao, GAN Kang, LIU Ling, DUAN Jun. Preventing Hospital Acquired Infection of Special Host in the Department of Critical Care Medicine--Organ Transplant Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 513-517. DOI: 10.12290/xhyxzz.2024-0054
[3]	LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
[4]	XU Fen, ZHOU Zhou. Heart Failure: Prevention and Treatment are Indispensable[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 953-957. DOI: 10.12290/xhyxzz.2022-0440
[5]	Chao WANG, Yang-yu ZHAO. Standardize Clinical Medication and Improve Maternal and Neonatal Outcomes: Interpretation on Prevention of Group B Streptococcal Early-onset Disease in Newborns: ACOG Committee Opinion, Number 797[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 402-407. DOI: 10.3969/j.issn.1674-9081.2020.04.008
[6]	Di ZHONG, Bo WU. Will the Strategies of Stroke Prevention Change with the New Diagnostic Standard of Hypertension?[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 103-107. DOI: 10.3969/j.issn.1674-9081.2019.02.003
[7]	Ying-xian SUN. Suggestion on China Mode of Prevention, Diagnosis and Treatment of Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 97-99. DOI: 10.3969/j.issn.1674-9081.2019.02.001
[8]	Fenglin Liu, Jing Qin. From Guidelines to Practice: Analysis of Guidelines for Prevention and Management of Perioperative Venous Thrombosis in General Surgery in China[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 144-149. DOI: 10.3969/j.issn.1674-9081.2018.02.008
[9]	Ying ZHANG, Jin-song GAO, Jun-tao LIU, Hai-yuan LIU, Ying-na SONG, Xiao-ming GONG, Zhi-jing SUN. Effectiveness of B-lynch Suture in Treatment and Prevention of Postpartum Hemorrhage[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 174-177. DOI: 10.3969/j.issn.1674-9081.2013.02.019
[10]	Ying-na SONG, Jun-tao LIU, Jian-qiu YANG, Xu-ming BIAN, Lei LI. Risk Factors, Labor Characteristics, and Outcomes of Shoulder Dystocia[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 169-173. DOI: 10.3969/j.issn.1674-9081.2013.02.018

Cited By

Cited by

Periodical cited type(1)

尹佳祺，赵雪丽，王静，刘丽文. 肥厚型心肌病猝死风险评估模型的研究进展. 中华心血管病杂志. 2024(07): 840-845 .

Other cited types(1)

Get Citation

PDF

XML

Article Metrics

Article views (1890) PDF downloads (139) Cited by(2)

Address：	Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
Tel：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
Copyright of website：	Editorial Office of Medical Journal of Peking Union Medical College Hospital

Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Catalog

Article Metrics

Related

Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(1)

Catalog

Article Metrics

Related

Export File

Citation

Format

Content